Table 1 Demographic and clinicopathological information for our serum- and tissue HFH/USP cohorts

From: Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas

 

Original cohort

Additional cohort

 

Liquid biopsy (serum)

Meningioma tissue

Meningioma

Non-meningioma

 

Meningioma (N = 63)

Non-meningioma (N = 141)

Confirmed recurrence (N = 35)

Confirmed non -recurrence (N = 15)

LB: serum (N = 20)

LB: plasma (N = 10)

Tumor tissue (N = 39)

LB: serum (N = 6)

Features

Median

(Q1, Q3)

Median

(Q1, Q3)

Median

(Q1, Q3)

Median

(Q1, Q3)

Median

(Q1, Q3)

Median

(Q1, Q3)

Median

(Q1, Q3)

Median

(Q1, Q3)

Age at diagnosis (yrs)

60

(45.5, 67.0)

54.0

(43.0, 64.0)

56.0

(49.5, 60.5)

55.0

(45.0, 60.5)

51.0

(46.8, 63.5)

51

(46.3, 60.3)

51

(46.5, 64)

49.0

(45, 55.5)

Person-time (mos)

31.6

(23.7, 49.0)

-

-

26.8

(6.1, 57.5)

102.1

(75.6, 137.4)

1.6

(0.1, 32.6)

1.6

(0.2, 3.5)

21.6

(3.4, 36.9)

-

-

MIB LI (%)

12.1

(4.5, 15.0)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sex

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

    Female

36

57.1

40

28.4

17

48.6

12

80

8

40

5

50

20

51.3

2

33.3

    Male

27

42.9

66

46.8

18

51.4

3

20

12

60

5

50

19

48.7

4

66.7

    Unknown

-

-

35

24.8

-

-

-

-

-

-

-

-

-

-

-

-

Race/Ethnicity

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

    Black or African American

10

15.9

17

12.1

3

8.6

2

13.3

5

25

5

50

8

20.5

1

16.7

    White

46

73

85

60.3

26

74.3

11

73.3

13

65

3

30

25

64.1

5

83.3

    Other

5

7.9

4

2.8

-

-

1

6.7

1

5

1

10

2

5.1

-

-

    Unknown

2

3.2

17

12.1

6

17.1

1

6.7

1

5

1

10

4

10.3

-

-

Post-surgical MRI report

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

    Stable disease

19

30.2

-

-

6

17.1

5

33.3

2

10

1

10

12

30.8

-

-

    Progressive disease

11

17.5

-

-

24

68.6

-

-

7

35

3

30

13

33.3

-

-

    Non-enhancing disease

29

46

-

-

3

8.6

10

66.7

2

10

-

-

3

7.7

-

-

    Unknown

4

12.7

-

-

2

5.7

-

-

9

45

6

60

11

28.2

-

-

Tumor Classification/Histopathological diagnosis

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

    Meningioma

63

100

-

-

35

100

15

100

20

100

10

100

39

100

-

-

    Not other specified (NOS)

23

36.5

-

-

1

2.9

1

6.7

8

40

3

30

10

25.6

-

-

    Atypical

24

38.1

-

-

25

71.4

8

53.3

8

40

4

40

16

41

-

-

    Anaplastic

8

33.3

-

-

5

14.3

-

-

-

-

-

-

5

12.8

-

-

    Rhabdoid

1

1.6

-

-

1

2.9

3

20

-

-

-

-

-

-

-

-

    Fibrous

1

1.6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

    Meningothelial

2

3.2

-

-

2

5.7

-

-

2

10

2

20

5

12.8

-

-

    Psammomatous

3

4.8

-

-

-

-

-

-

1

5

1

10

1

2.6

-

-

    Secretory

1

1.6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

    Chordoid

-

-

-

-

-

-

1

6.7

-

-

-

-

-

-

-

-

    Transitional

-

-

-

-

1

2.9

2

13.3

1

5

-

-

2

5.2

-

-

    Glioma

-

-

109

77.3

-

-

-

-

-

-

-

-

-

-

-

-

    Pituitary tumor

-

-

14

9.9

-

-

-

-

-

-

-

-

-

-

-

-

    Non-tumor

-

-

6

4.3

-

-

-

-

-

-

-

-

-

-

1

16.7

    Other

-

-

12

8.5

-

-

-

-

-

-

-

-

-

-

5

83.3

    CNS lymphoma

-

-

4

33.3

-

-

-

-

-

-

-

-

-

-

-

-

    Other CNS diseases

-

-

8

66.7

-

-

-

-

-

-

-

-

-

-

5

100

WHO grade

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

    1

30

47.6

-

-

4

11.4

3

20

12

60

6

60

19

48.7

-

-

    2

24

38.1

7

4.8

25

71.4

9

60

8

40

4

40

16

41

-

-

    3

9

14.3

6

4.1

6

17.1

3

20

-

-

-

-

4

10.3

-

-

    4

-

-

77

53.1

-

-

-

-

-

-

-

-

-

-

-

-

    Unknown

-

-

28

19.3

-

-

-

-

-

-

-

-

-

-

-

-

    Not applicable

-

-

27

18.6

-

-

-

-

-

-

-

-

-

-

6

100

Tumor locationa

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

    Calvarium

42

66.7

-

-

28

80

8

53.3

16

80

8

80

26

66.6

-

-

    Anterior fossa

5

7.9

-

-

-

-

-

-

1

5

1

10

1

2.6

-

-

    Middle fossa

7

11.1

-

-

3

8.6

6

40

-

-

-

-

2

5.2

-

-

    Posterior fossa

2

3.2

-

-

1

2.9

-

-

2

10

-

-

3

7.6

-

-

    Spinal

3

4.8

-

-

-

-

-

-

1

5

1

10

4

10.2

-

-

    Other (orbital, other)

3

4.8

-

-

-

-

-

-

-

-

-

-

2

5.2

-

-

    Unknown

1

1.6

-

-

3

8.6

1

6.7

-

-

-

-

1

2.6

-

-

Time of Collection

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

    Primary

44

69.8

65

44.8

18

51.4

12

80

11

55

2

20

23

48.9

-

-

    Recurrent

19

30.2

56

38.6

17

48.6

3

20

9

45

8

80

16

41.1

-

-

    Follow-up (OT)

-

-

6

4.1

-

-

-

-

-

-

-

-

-

-

-

-

    Not applicable

-

-

8

5.5

-

-

-

-

-

-

-

-

-

-

6

100

    Unknown

-

-

10

6.9

-

-

-

-

-

-

-

-

-

-

-

-

Extent of resection

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

    Gross total (GTR)

40

63.5

-

-

22

62.9

15

100

5

25

2

20

14

-

-

-

    Sub-total (STR)

21

33.3

-

-

13

37.1

-

-

4

20

4

40

10

-

-

-

    Unknown

2

3.2

-

-

-

-

-

-

11

55

4

40

15

-

-

-

Presurgical treatment

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

    Embolization

12

19.1

-

-

1

2.9

-

-

-

-

-

-

1

2.6

-

-

    Radiotherapy

25

39.7

-

-

23

65.7

2

13.3

5

25

4

40

17

43.6

-

-

Tumor recurrence

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

    Confirmed recurrence

16

25.4

-

-

35

100

-

-

8

40

4

40

25

64.1

-

-

    Confirmed non-recurrence

9

14.3

-

-

-

-

15

100

-

-

-

-

2

5.1

-

-

    Unknown

38

60.3

-

-

-

-

-

-

12

60

6

60

12

30.8

-

-

Last report status

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

    Alive

57

90.5

43

30.5

5

14.3

15

100

20

100

10

100

28

71.8

4

66.7

    Dead

5

7.9

46

32.6

30

85.7

-

-

-

-

-

-

11

28.2

2

33.3

    Unknown

1

1.6

52

36.9

-

-

-

-

-

-

-

-

-

-

-

-

  1. LB liquid biopsy, LI labeling indices, OT off-treatment.
  2. aLocations based on Yuzawa et al., 2016.
Back to article page